Effects of Different Doses of Butorphanol on Perioperative Analgesia, Recovery, and Immune Function in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer: A Randomized Controlled Trial
To investigate the optimal dose of butorphanol for patient-controlled intravenous analgesia (PCIA) by evaluating its effects on perioperative pain control and immune function in patients undergoing ovarian cancer surgery. Patients undergoing ovarian cancer surgery between May 2023 and March 2025 were randomized into four PCIA groups: Group S (sufentanil 0.04 μg·kg VAS score at T3 was lower in group B3 than in S ( High-dose butorphanol PCIA effectively relieves postoperative pain and reduces time to early ambulation without affecting immune indicators within 48 h postoperatively.
